- Home
- OPP vs OABI Comparison
OPP vs OABI Comparison
Compare OPP & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPP
- OABI
- Stock Information
- Founded
- OPP 2010
- OABI 2012
- Country
- OPP United States
- OABI United States
- Employees
- OPP N/A
- OABI N/A
- Industry
- OPP Finance/Investors Services
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- OPP Finance
- OABI Health Care
- Exchange
- OPP Nasdaq
- OABI Nasdaq
- Market Cap
- OPP 204.0M
- OABI 227.4M
- IPO Year
- OPP N/A
- OABI N/A
- Fundamental
- Price
- OPP $8.27
- OABI $1.66
- Analyst Decision
- OPP
- OABI Strong Buy
- Analyst Count
- OPP 0
- OABI 3
- Target Price
- OPP N/A
- OABI $6.67
- AVG Volume (30 Days)
- OPP 108.0K
- OABI 555.0K
- Earning Date
- OPP 01-01-0001
- OABI 11-04-2025
- Dividend Yield
- OPP 14.41%
- OABI N/A
- EPS Growth
- OPP N/A
- OABI N/A
- EPS
- OPP N/A
- OABI N/A
- Revenue
- OPP N/A
- OABI $23,027,000.00
- Revenue This Year
- OPP N/A
- OABI N/A
- Revenue Next Year
- OPP N/A
- OABI $48.74
- P/E Ratio
- OPP N/A
- OABI N/A
- Revenue Growth
- OPP N/A
- OABI 6.05
- 52 Week Low
- OPP $7.26
- OABI $1.22
- 52 Week High
- OPP $8.83
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- OPP 37.88
- OABI 49.60
- Support Level
- OPP $8.22
- OABI $1.58
- Resistance Level
- OPP $8.42
- OABI $1.80
- Average True Range (ATR)
- OPP 0.10
- OABI 0.10
- MACD
- OPP -0.02
- OABI 0.01
- Stochastic Oscillator
- OPP 31.58
- OABI 29.38
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.